PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
DRD2	4	CALM1	0	pull down	Park SK (2005)	1
ADORA2A	0	DRD2	4	affinity chromatography technology, fluorescent resonance energy transfe	Kamiya T (2003), Kamiya T (2003)	2
DRD2	4	FLNA	10	affinity chromatography technology	Binda AV (2002)	1
DRD2	4	COLEC12	2	affinity chromatography technology	Huttlin EL (2017)	1
DRD2	4	KCNJ5	0	affinity chromatography technology	Lavine N (2002)	1
DRD2	4	PPP1R9B	1	two hybrid, pull down	Smith FD (1999), Smith FD (1999)	2
FLNA	10	CALM1	0	affinity chromatography technology	Hein MY (2015)	1
GNB5	2	DRD2	4	imaging technique, protein complementation assay	Octeau JC (2014), Octeau JC (2014)	2
KCNJ3	2	KCNJ5	0	pull down, genetic interference, affinity chromatography technology	Huang CL (1997), He C (2002), Huttlin EL (2017)	3
ARRB2	5	DRD2	4	imaging technique	Octeau JC (2014)	1
EGFR	5	ARRB2	5	two hybrid, protein complementation assay	Kotlyar M (2015), Petschnigg J (2014)	2
DRD2	4	KCNJ6	6	affinity chromatography technology	Lavine N (2002)	1
DRD2	4	CLIC6	2	two hybrid	Griffon N (2003)	1
EGFR	5	DRD2	4	affinity chromatography technology	Yao Z (2017)	1
DRD2	4	EPB41L1	4	pull down, two hybrid	Binda AV (2002), Binda AV (2002)	2
DRD2	4	KCNJ3	2	affinity chromatography technology	Lavine N (2002)	1
DRD2	4	WDR45	23	affinity chromatography technology	Huttlin EL (2017)	1
NDFIP1	0	EGFR	5	affinity chromatography technology	Mund T (2010)	1
NCS1	2	DRD2	4	pull down, affinity chromatography technology, affinity chromatography technology, two hybrid, two hybrid	Kabbani N (2002), Kabbani N (2002), Kabbani N (2002), Kabbani N (2002), Kabbani N (2002)	5
DRD2	4	NDFIP1	0	affinity chromatography technology	Huttlin EL (2017)	1
EGFR	5	CALM1	0	affinity chromatography technology, affinity chromatography technology, two hybrid, protein complementation assay, pull down	Li H (2004), Wu SL (2006), Kotlyar M (2015), Petschnigg J (2014), Aifa S (2002)	5
ARRB2	5	FLNA	10	affinity chromatography technology, affinity chromatography technology	Xiao K (2007), Boularan C (2007)	2
DRD2	4	PAWR	2	pull down, two hybrid	Park SK (2005), Park SK (2005)	2
DRD2	4	MSRA	3	affinity chromatography technology	Huttlin EL (2017)	1
FLNA	10	PPP1R9B	1	affinity chromatography technology	Hein MY (2015)	1